10-Hydroxy-cis-12-octadecenoic acid alkyl ester and its use
By combining 10-hydroxy-cis-12-octadecanoic acid with mono- or dialkanol to form an alkyl ester compound that is liquid at room temperature, the problems of HYA solid state and taste stimulation are solved, and the problem of HYA solid state and taste stimulation is achieved. Effective application and excellent physiological functions in the fields of food, medicine and cosmetics.
Patent Information
- Application Number
- CN201680045377.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-06-02
- Filing Date
- 2016-06-02
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2036-06-02
AI Technical Summary
10-hydroxy-cis-12-octadecanoic acid (HYA) is solid at room temperature, has poor uptake and operability, and has a irritating smell, limiting its application.
10-hydroxy-cis-12-octadecanoate alkyl ester or its optical isomer was developed to make it liquid at room temperature, and HYA was combined with monomer or dialcohol through esterification reaction to form Compounds that can be used for edible oils, foods, medicines, cosmetics and feeds.
The liquid state and good taste of HYA are achieved, making it easier to absorb and operate, and at the same time, it exerts excellent physiological functions after hydrolysis through ester bonds in the body, such as improved lipid metabolism, improved intestinal immunity and inhibition of intestinal inflammation .
Smart Images

Figure GDA0005046882380000071 
Figure GDA0005046882380000072 
Figure GDA0005046882380000081
Abstract
Description
Technical Field
[0001] The present invention relates to an alkyl ester of 10-hydroxy-cis-12-octadecenoic acid (hereinafter, also referred to as "HYA"), an ester with a dihydric alkanol, or an optical isomer thereof. In addition, the present invention also relates to the use of the ester or its optical isomer as an edible fat and oil, and a composition (food, medicine, cosmetic, feed, etc.) containing the ester or its optical isomer. Background Art
[0002] In recent years, the physiological functions of rare fatty acids that exist only in a low proportion in vivo have attracted attention. For example, it is reported that conjugated fatty acids such as conjugated linoleic acid (non-patent document 1), ω3 polyunsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid (patent document 1) have lipid metabolism improvement effects, diabetes improvement effects, etc. For taking the above rare fatty acids with meals as functional lipids, it has received great attention, and products (foods, etc.) containing them have entered the market.
[0003] One of rare fatty acids includes hydroxylated fatty acids with hydroxyl groups in compounds. Up to now, there is no suitable supply source, and its physiological function has not yet been fully analyzed. Recently, it has been found that the linoleic acid etc. contained in a large number of vegetable oils are used as starting raw materials, and enzyme reactions are used to efficiently and selectively manufacture the method (patent document 2). Moreover, while the supply method of various hydroxylated fatty acids can be ensured, the research on its physiological function is also actively carried out. In hydroxylated fatty acids, the inventors especially focus on 10-hydroxy-adaptive-12-octadecenoic acid (HYA), and it is reported that HYA has an abnormal lipid metabolism improvement effect (patent document 3), an intestinal immunity improvement effect (patent document 4), an intestinal inflammation inhibitory effect (non-patent document 2) etc.
[0004] Since it is easy to obtain high-purity HYA as described above, if HYA can be easily ingested, it is expected that its physiological functions will be utilized to promote the effective use of HYA. However, there are the following problems: HYA has a melting point of about 25°C (here, "about" means ±1°C) and is solid (or partially liquid) at room temperature. Therefore, compared with liquid ingredients, its ease of ingestion and the operability when adding or mixing with other liquid or solid food ingredients are poor. In addition, the pungent taste of HYA itself also becomes an obstacle to ingestion.
[0005] On the other hand, no HYA derivatives capable of solving the above-mentioned problems have been reported so far.
[0006] Regarding alkyl esters of HYA, there are reports that 10-hydroxy-cis-12-octadecenoic acid methyl ester and 10-hydroxy-cis-12-octadecenoic acid ethyl ester are used as production intermediates of sebacic acid (Patent Document 5), but they have not been used except for the use as such production intermediates. In addition, alkyl esters of HYA other than 10-hydroxy-cis-12-octadecenoic acid methyl ester and 10-hydroxy-cis-12-octadecenoic acid ethyl ester have not been reported so far.
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: Japanese Patent Application No. 2006-521368
[0010] Patent Document 2: International Publication No. 2013 / 168310
[0011] Patent Document 3: International Publication No. 2014 / 069227
[0012] Patent Document 4: International Publication No. 2014 / 129384
[0013] Patent Document 5: International Publication No. 2014 / 037328
[0014] Non-patent literature
[0015] Non-patent document 1: Nagao, K., J. Biosci. Bioeng., 2005, vol. 100, no. 2, p. 152-157
[0016] Non-patent document 2: Miyamoto, J., et al., J. Biol. Chem., 2015, 290(5), 2902-2918 Summary of the invention
[0017] Problem that the invention aims to solve
[0018] An object of the present invention is to provide a novel HYA derivative which has the excellent physiological function of HYA and is easy to ingest and handle.
[0019] Solutions to the problem
[0020] The present inventors have conducted intensive studies in view of the above problems and have found that 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof is liquid at room temperature and has a good taste. Further studies have led to the completion of the present invention.
[0021] That is, the present invention is as follows:
[0022] [1] 10-hydroxy-cis-12-octadecenoic acid alkyl ester or its optical isomer (except 10-hydroxy-cis-12-octadecenoic acid methyl ester and 10-hydroxy-cis-12-octadecenoic acid ethyl ester).
[0023] [2] The 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof according to [1] above, which is liquid at room temperature.
[0024] [3] An edible fat or oil comprising 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof.
[0025] [4] A food or food additive containing 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof.
[0026] [5] A pharmaceutical composition comprising 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof.
[0027] [6] A preventive or therapeutic agent for a disease, comprising 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof, wherein the disease is selected from obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, ulcer, ulcerative colitis, Crohn's disease, irritable bowel syndrome, and inflammatory diseases.
[0028] [7] A cosmetic or cosmetic additive comprising 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof.
[0029] [8] A feed or a feed supplement containing 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof.
[0030] [9] Esters of 10-hydroxy-cis-12-octadecenoic acid and diols or their optical isomers.
[0031]
[10] The ester or optical isomer thereof according to [9] above, which is liquid at room temperature.
[0032]
[11] A food or food additive containing the ester according to [9] or
[10] or an optical isomer thereof.
[0033]
[12] A pharmaceutical composition comprising the ester according to [9] or
[10] or an optical isomer thereof.
[0034]
[13] A cosmetic or cosmetic additive comprising the ester according to [9] or
[10] or an optical isomer thereof.
[0035] Effects of the Invention
[0036] According to the present invention, esters of 10-hydroxy-cis-12-octadecenoic acid and monovalent or divalent alkanols (10-hydroxy-cis-12-octadecenoic acid alkyl esters and alkylene glycol 10-hydroxy-cis-12-octadecenoic acid esters) and their optical isomers (hereinafter, these are also simply collectively referred to as "compounds of the present invention"). The compounds of the present invention are derivatives of HYA that are liquid at room temperature, have a good taste, and are easy to ingest and handle.
[0037] In addition, after ingestion, the compound of the present invention will hydrolyze the ester bond in the molecule by lipase or the like in the body to release HYA, and therefore, it can be expected to exert excellent physiological functions (improvement of lipid metabolism abnormalities, improvement of intestinal immunity, suppression of intestinal inflammation, etc.) in the same manner as ingestion of HYA alone.
[0038] Therefore, the compound of the present invention having the above-mentioned functions can be used as edible oils and fats, and can also be used as various foods and food additives. Furthermore, it can be used in various fields such as medicines, cosmetics, and feeds, and is therefore extremely useful industrially. DETAILED DESCRIPTION
[0039] Hereinafter, the present invention will be described in detail.
[0040] (definition)
[0041] In the present specification, "acyl" means an alkanoyl group, an alkenoyl group or an aroyl group.
[0042] The alkanoyl group refers to a formyl group or a linear or branched alkylcarbonyl group, and examples thereof include a formyl group, an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, a hexanoyl group, and a heptanoyl group.
[0043] The alkenoyl group means a straight-chain or branched alkenylcarbonyl group, and examples thereof include an acryloyl group, a crotonoyl group, and an oleoyl group.
[0044] The aroyl group means an arylcarbonyl group, and examples thereof include a benzoyl group and a naphthoyl group.
[0045] In this specification, "alkyl" refers to a linear or branched alkyl group with one or more carbon atoms. In particular, when the number of carbon atoms is not limited, it is usually C 1-40 Alkyl, preferably C 1-20 Alkyl, particularly preferably C 1-6 Alkyl, most preferably C 1-3 alkyl.
[0046] In this manual, “C 1-40The term "alkyl" refers to a linear or branched alkyl group having 1 to 40 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, hexadecyl, octadecyl, eicosyl, tetracosyl, octacosyl, triacontyl, dotriacontyl, hexatriacontyl, and tetracontyl.
[0047] In this manual, “C 1-20 The term "alkyl" refers to a linear or branched alkyl group having 1 to 20 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, hexadecyl, octadecyl, and eicosyl.
[0048] In this manual, “C 1-6 The term "alkyl" refers to a linear or branched alkyl group having 1 to 6 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl.
[0049] In this manual, “C 1-3 The term "alkyl" refers to a linear or branched alkyl group having 1 to 3 carbon atoms, and examples thereof include methyl, ethyl, propyl, isopropyl, and the like.
[0050] In the present specification, the "alkyl ester" in "10-hydroxy-cis-12-octadecenoic acid alkyl ester" or "alkyl ester of fatty acid" refers to an ester formed by an alcohol (monohydric alkanol) having an alkyl group as defined above and 10-hydroxy-cis-12-octadecenoic acid or fatty acid. In addition, the alkyl group constituting the "alkyl ester" may be substituted.
[0051] In the present specification, "alkylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester" and "alkylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester" refer to the monoester and diester of a dihydric alkane alcohol (alkanediol) and 10-hydroxy-cis-12-octadecenoic acid, respectively. In addition, the alkylene glycol constituting the monoester or diester may be substituted.
[0052] The "alkylene glycol" mentioned above refers to a divalent straight-chain or branched alkanol (alkanediol). The alkylene glycol in the present invention is usually C 1-8 Alkylene glycol, preferably C 2-6 Alkylene glycol, more preferably C 2-4 Alkylene glycol: The two hydroxyl groups in the alkylene glycol may be bonded to any position of the alkylene chain as long as they can form an ester with 10-hydroxy-cis-12-octadecenoic acid.
[0053] Here, "C 1-8 "Alkylene glycol" refers to a dihydric alcohol having 1 to 8 carbon atoms. 2-6 "Alkylene glycol" refers to a dihydric alcohol having 2 to 6 carbon atoms. 2-4 "Alkylene glycol" refers to a dihydric alkanol having 2 to 4 carbon atoms.
[0054] Specific examples of the alkylene glycol include methylene glycol (methylene glycol), ethylene glycol (ethylene glycol), 1,2-propylene glycol (1,2-propylene glycol), 1,3-propylene glycol (1,3-propylene glycol), 1,3-butylene glycol (1,3-butylene glycol), 1,2-pentylene glycol (1,2-pentanediol), 1,2-hexylene glycol (1,2-hexanediol), hexylene glycol (2-methyl-2,4-pentanediol), 1,2-octylene glycol (1,2-octanediol), etc., and ethylene glycol (ethylene glycol), 1,2-propylene glycol (1,2-propylene glycol), 1,3-propylene glycol (1,3-propylene glycol), 1,3-butylene glycol (1,3-butylene glycol), 1,2-pentylene glycol (1,2-pentanediol), 1,2-hexylene glycol (1,2-hexanediol), hexylene glycol (2-methyl-2,4-pentanediol), etc., and more preferably ethylene glycol (ethylene glycol), 1,2-propylene glycol (1,2-propylene glycol), 1,3-propylene glycol (1,3-propylene glycol), 1,3-butylene glycol (1,3-butylene glycol), etc.
[0055] In this specification, "alkylene" refers to a divalent substituent of a linear or branched alkane having one or more carbon atoms, usually C 1-8 Alkylene, preferably C 2-6 Alkylene, more preferably C 2-4 Alkylene.
[0056] In this manual, “C 1-8The term "alkylene" refers to a linear or branched alkylene group having 1 to 8 carbon atoms, and examples thereof include methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, pentylene, 1-propylethylene, hexylene, 1-butylethylene, 1,1,3-trimethylpropylene, heptylene, octylene, and 1-hexylethylene.
[0057] In this manual, “C 2-6 The term "alkylene" refers to a linear or branched alkylene group having 2 to 6 carbon atoms, and examples thereof include ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, pentylene, 1-propylethylene, hexylene, 1-butylethylene, and 1,1,3-trimethylpropylene.
[0058] In this manual, “C 2-4 The term "alkylene" refers to a linear or branched alkylene group having 2 to 4 carbon atoms, and examples thereof include ethylene, propylene, 1-methylethylene, butylene, and 1-methylpropylene.
[0059] In the present specification, "optionally substituted" means that it optionally has one or more substituents. The "substituent" is not particularly limited, and examples thereof include a halogen atom, an optionally protected hydroxyl group (e.g., a hydroxyl group, a C 1-6 Alkoxy, C 1-7 Alkanoyloxy, C 7-11 Aroyloxy, C 1-6 Alkylsulfonyloxy, C 6-10 arylsulfonyloxy, hydroperoxy, etc.), optionally protected thiol (e.g., thiol, methylthio, acetylthio, etc.), optionally protected carboxyl (e.g., carboxyl, C 1-6 alkoxy-carbonyl, etc.), optionally protected amino (e.g., amino, methylamino, acetylamino, dimethylamino, etc.), acyl (e.g., C 1-7 Alkanoyl, C 7-11 Aroyl, etc.), optionally C 1-6 Alkyl-substituted carbamoyl, nitro, cyano, C 3-8 Cycloalkyl, ethylene oxide, C 6-10 Aryl, etc. When there are a plurality of substituents, each substituent may be the same or different.
[0060] In the present specification, "optionally protected hydroxyl", "optionally protected thiol", "optionally protected carboxyl" or "optionally protected amino" refers to a hydroxyl, thiol, carboxyl or amino group that is optionally protected by a "protecting group". As the "protecting group", for example, the protecting groups for hydroxyl, thiol, carboxyl or amino described in Protective Groups in Organic Synthesis, John Wiley and Sons (1980) can be used, and examples thereof include: C 1-6 Alkyl, C 7-14 Aralkyl, C 6-10 Aryl, C 1-7 Alkanoyl, C 7-14 Aralkyl-carbonyl, tri-C 1-6 The above-mentioned protecting groups may be further replaced by halogen atoms, C 1-6 Alkyl, C 1-6 In addition, the "optionally protected hydroxyl group", "optionally protected thiol group", "optionally protected carboxyl group" or "optionally protected amino group" also include groups derived from natural substances such as sugars, amino acids, fatty acids, nucleic acids, phosphoric acid, sulfuric acid, etc., bonded to hydroxyl groups, thiol groups, carboxyl groups or amino groups.
[0061] (Compound of the present invention)
[0062] As one embodiment of the present invention, the compound of the present invention is 10-hydroxy-cis-12-octadecenoic acid alkyl ester or an optical isomer thereof (hereinafter also referred to as "compound (1) of the present invention" in the present specification).
[0063] In addition, as another embodiment of the present invention, the compound of the present invention is a monoester formed by 10-hydroxy-cis-12-octadecenoic acid and a dihydric alkanol (also referred to as "alkylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester") or an optical isomer thereof (hereinafter also referred to as "compound (2) of the present invention" in this specification).
[0064] As another embodiment of the present invention, the compound of the present invention is a diester formed by 10-hydroxy-cis-12-octadecenoic acid and a dihydric alkanol ("also referred to as alkylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester") or an optical isomer thereof (hereinafter also referred to as "compound (3) of the present invention" in this specification).
[0065] The compound (1) of the present invention is specifically a 10-hydroxy-cis-12-octadecenoic acid alkyl ester represented by the following formula (I) or an optical isomer thereof.
[0066] [Chemical formula 1]
[0067]
[0068] (Where R 1 represents an optionally substituted alkyl group. )
[0069] In formula (I), with respect to R 1 The optionally substituted alkyl group is as defined above.
[0070] The compound (1) of the present invention may be an ester formed by one monohydric alkanol and 10-hydroxy-cis-12-octadecenoic acid, or may be a mixture of esters formed by two or more monohydric alkanols and 10-hydroxy-cis-12-octadecenoic acid.
[0071] The compound (2) of the present invention is specifically an alkylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester represented by the following formula (II) or an optical isomer thereof.
[0072] [Chemical formula 2]
[0073]
[0074] (Where R 2 represents the residue of an optionally substituted alkylene glycol. )
[0075] In formula (II), R 2 The optionally substituted alkylene glycol residue represented by is the alkylene glycol residue defined above.
[0076] The compound (2) of the present invention may be a monoester formed by one dihydric alkanol (alkylene glycol) and 10-hydroxy-cis-12-octadecenoic acid, or may be a mixture of monoesters formed by two or more dihydric alkanols (alkylene glycols) and 10-hydroxy-cis-12-octadecenoic acid.
[0077] The compound (3) of the present invention is specifically an alkylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester represented by the following formula (III) or an optical isomer thereof.
[0078] [Chemical formula 3]
[0079]
[0080] (In the formula, X represents an optionally substituted alkylene group.)
[0081] In the formula (III), the optionally substituted alkylene group represented by X is as defined above.
[0082] The compound (3) of the present invention may be a diester formed from one dihydric alkanol (alkylene glycol) and 10-hydroxy-cis-12-octadecenoic acid, or may be a mixture of diesters formed from two or more dihydric alkanols (alkylene glycols) and 10-hydroxy-cis-12-octadecenoic acid.
[0083] When the compounds (1) to (3) of the present invention have isomers such as optical isomers, stereoisomers, positional isomers, etc., any isomers thereof and mixtures thereof are also included in the compounds (1) to (3) of the present invention. They can be obtained in the form of optically pure compounds by known synthesis methods, separation methods (based on recrystallization, separation by high performance liquid chromatography using an optically active column, enzymatic methods, etc.). These optical isomers can be used in a mixed state, or optically pure compounds obtained by separation can be used alone, or they can be used in combination.
[0084] The compounds (1) to (3) of the present invention are preferably liquid at room temperature. In the present specification, room temperature refers to room temperature (15°C to 25°C) specified in the 16th revised edition of the Japanese Pharmacopoeia General Rules and the 17th revised edition of the Japanese Pharmacopoeia General Rules.
[0085] It should be noted that among the compounds of the present invention, the compounds (2) and (3) of the present invention can also be used as foods or food additives, but are particularly suitable for use as compositions for parenteral administration in the pharmaceutical compositions described below, and as cosmetics or cosmetic additives.
[0086] (Method for producing the compound of the present invention)
[0087] There is no particular limitation on the method for preparing the compound of the present invention, and examples thereof include: a method for esterification by reacting HYA or an activated form thereof (e.g., acyl halide, active ester, acid anhydride, etc.) with an alkanol (monovalent or divalent alkanol) (method 1), and a method for transesterification by reacting HYA or an activated form thereof (e.g., acyl halide, active ester, acid anhydride, etc.) with an alkyl ester or alkylene glycol ester of a fatty acid (hereinafter referred to as fatty acid ester) (method 2). When selecting a method and reaction conditions, the preferred ones can be selected in consideration of the stability of the raw material compound and the product, and a plurality of methods can be combined. Further, reaction steps such as protection and deprotection can be appropriately introduced as needed.
[0088] HYA used in each of the above-mentioned production methods can be prepared by the method described in Patent Document 2. The alkanol and fatty acid or activated forms thereof (e.g., acid halides, active esters, acid anhydrides, etc.) used in each of the above-mentioned production methods can be commercially available products, or can be synthesized from commercially available raw material compounds by a method known per se or a method based thereon.
[0089] Next, the preparation method 1 of the compound of the present invention is described.
[0090] The esterification step in the production method 1 can be carried out by using an enzyme reaction or a chemical reaction, but it is preferable to use an enzyme reaction because the reaction operation is simple and the reaction conditions are mild.
[0091] The enzyme used in the esterification reaction of the production method 1 is not particularly limited as long as it can convert the compound of the present invention. Examples thereof include lipase and esterase, and among them, lipase is preferred.
[0092] Lipase can be obtained as a commercial product from Novozymes, Amano Enzyme, Meito Sangyo Co., Ltd., Sigma-Aldrich, and the like.
[0093] The alkanol used as the reaction substrate in the production method 1 can be used without particular limitation as long as it is a monohydric or dihydric alkanol that can give the compound of the present invention by an esterification reaction with HYA.
[0094] Examples of the monohydric alkanol include alkanols having 1 to 40 carbon atoms, and among them, methanol, ethanol, propanol, and the like are preferred.
[0095] Examples of the divalent alkanol include alkanediol having 1 to 8 carbon atoms, preferably alkanediol having 2 to 6 carbon atoms, and more preferably alkanediol having 2 to 4 carbon atoms, such as ethylene glycol, propylene glycol, and butanediol.
[0096] In the esterification step of Preparation Method 1, it is desirable that the water content in the reaction substrate and the solvent is as low as possible so that the compounds (1) to (3) of the present invention as the reaction products will not be hydrolyzed. The reaction can be carried out without a solvent or in various non-aqueous solvents (e.g., non-polar solvents such as n-heptane, n-hexane, isooctane, etc.), and the reaction without a solvent is more preferred. Furthermore, in order to remove water from the reaction system to shift the equilibrium of the reaction, promote the esterification reaction, or reduce the water content in the reaction substrate and the solvent used, the reaction can also be carried out under reduced pressure.
[0097] The reaction temperature in Preparation Method 1 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the state of HYA as a reaction substrate (type of activated form, etc.), the type of alkanol, etc., but is generally 4°C to 100°C, preferably 20°C to 70°C, and more preferably 30°C to 50°C.
[0098] The reaction time in Preparation Method 1 varies depending on the presence or absence of a solvent, the type of solvent when a solvent is used, the type of enzyme, the state of HYA as a reaction substrate (type of activated form), the type of alkanol, etc., but is generally 1 hour to 168 hours, preferably 5 hours to 48 hours.
[0099] The amount of HYA and alkanol used as the reaction substrate in Preparation 1 also depends on the type of alkanol used, but is preferably 0% to 1000% by weight, more preferably 30% to 500% by weight, and particularly preferably 50% to 300% by weight relative to HYA1.
[0100] The amount of the enzyme used is preferably 1 to 100% by weight, more preferably 1 to 50% by weight, and particularly preferably 1 to 20% by weight, relative to HYA used as a reaction substrate in Preparation Method 1.
[0101] The enzyme used for enzyme reaction used in the above-mentioned preparation method 1 can be an enzyme immobilized on various carriers or a free enzyme, but from the aspect that the activity is high and can be recovered and repeatedly used even in an anhydrous reaction system or a reaction system with less water, an immobilized enzyme is more preferred. The above-mentioned enzyme can be either a purified enzyme or a crude purified product. Alternatively, the enzyme can be expressed by a bacterium such as Escherichia coli and the bacterium itself can be used, or the culture fluid of the bacterium can be used.
[0102] (Edible fats and oils of the present invention)
[0103] The present invention provides edible fats and oils containing the compound of the present invention (hereinafter also referred to as "edible fats and oils of the present invention" in this specification).
[0104] That is, the compound of the present invention can be used as edible fats and oils alone or in combination with other edible fats and oils. The content of the compound of the present invention in the edible fats and oils of the present invention is not particularly limited, and is usually equivalent to more than 5% by weight of the total amount of edible fats and oils, preferably more than 20% by weight, and more preferably more than 50% by weight. From the aspect of obtaining excellent taste and physiological functions, it is particularly preferred to use it alone as edible fats and oils.
[0105] In the edible oil of the present invention, conventional ingredients (food additives, etc.) for edible oils and fats may be contained within the scope that does not destroy the characteristics of the present invention. As these ingredients, for example, emulsifiers, antioxidants / anti-deterioration agents, defoamers, crystal modifiers, etc. may be cited.
[0106] Examples of the emulsifier include fatty acid glycerides, polyglycerol fatty acid esters, sucrose fatty acid esters, polyglycerol condensed ricinoleic acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, and organic acid monoglycerides.
[0107] Examples of the antioxidant / anti-degradation agent include tocopherols, flavonoid derivatives, gallic acid derivatives, catechins and their esters, lignans (such as sesamin), fucic acid, sesamol, and terpenes.
[0108] Examples of the defoaming agent include silicone oil and the like.
[0109] Examples of the crystal modifier include triacylglycerol, diacylglycerol, monoglyceride, heptaglyceride, decaglyceride, decaglyceride, waxes, and sterol esters.
[0110] In addition, spices, colorants, etc. may be added. Examples of spices include capsaicin, anethole, eugenol, eucalyptol, zingerone, etc. Examples of colorants include carotene, astaxanthin, etc.
[0111] Furthermore, the edible oils and fats of the present invention may also contain various nutrients (sugars, proteins, etc.), various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.), and various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.) as needed.
[0112] (Food or food additive of the present invention)
[0113] The present invention provides a food or a food additive containing the compound of the present invention (hereinafter also referred to as "the food or food additive of the present invention" in this specification).
[0114] The food or food additive of the present invention is not particularly limited as long as it is in an orally ingestible form such as a solution, a suspension, an emulsion, a gel, a powder, or a solid molded product.
[0115] Specific examples of the food or food additive of the present invention include: supplements (powders, granules, soft capsules, hard capsules, tablets, chewable tablets, rapidly disintegrating tablets, syrups, liquids, etc.), beverages (carbonated beverages, lactic acid beverages, sports drinks, fruit juice drinks, vegetable beverages, soy milk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, nutritional beverages, alcoholic beverages, etc.), snacks (soft gelatin, jelly, chewing gum, chocolate, cookies, candy, caramel, Japanese snacks, snacks, etc.), fast food (instant noodles, soft canned foods, canned foods, microwave foods, instant soups / miso soups, freeze-dried foods, etc.), oily foods (mayonnaise, salad dressing, butter, cream, margarine, etc.), flour products (bread, pasta, noodles, cake flour, bread crumbs, etc.), seasonings (sauces, tomato processed seasonings, flavor seasonings, cooking combinations, soups, etc.), livestock processed products (meat ham / sausages, etc.), etc.
[0116] The content of the compound of the present invention in the food or food additive of the present invention is 5 to 90% by weight, preferably 10 to 80% by weight, and more preferably 20 to 70% by weight, relative to the total amount of the food or food additive.
[0117] The daily intake of the food or food additive of the present invention can be appropriately set according to the age of the subject to be ingested, the condition, state and severity of the condition expected to be improved by ingestion, the dosage form of the food, etc., and the intake of the compound of the present invention is preferably set to the same degree as the daily dosage described later.
[0118] The food or food additive of the present invention can be formulated with various nutrients (sugars, proteins, etc.), various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K, etc.), various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), dietary fiber, foods reported to have physiological functions (royal jelly, propolis, chitin, etc.), etc. as needed.
[0119] In addition, conventional food additives may be added to the food or food composition of the present invention as needed, such as emulsifiers (glycerol fatty acid esters, sucrose fatty acid esters, etc.), thickeners and stabilizers (pectin, sodium carboxymethyl cellulose, etc.), antioxidants (mixed vitamin E, sodium isoascorbate, etc.), preservatives (sodium benzoate, sorbic acid, etc.), glossing agents (shellac, beeswax, etc.), sweeteners (xylitol, aspartame, etc.), acidulants (citric acid, malic acid, etc.), bittering agents (naringin, etc.), seasonings (sodium L-glutamate, disodium 5'-inosinic acid, etc.), coloring agents (gardenia yellow, red No. 2, etc.), flavors (sweet orange flavor, vanillin, etc.), manufacturing agents (salt water, binders, etc.), etc.
[0120] The food or food additive of the present invention can be prepared by adding the above-mentioned various nutrients, various vitamins, etc., and conventional food additives to the compound of the present invention as required, and using conventional production methods.
[0121] It should be noted that the edible oils and fats, foods or food additives of the present invention also include those classified as health foods, functional foods, health functional foods (for example, specific health foods, functional foods, etc.), special purpose foods (for example, foods for patients, etc.), edible oils and fats and foods marked with disease risk reduction labels, etc.
[0122] Here, as a "disease risk reduction mark", for example, there can be cited: a mark indicating that it is a substance for treating, improving, inhibiting and / or preventing a disease that can be improved by HYA. Therefore, the edible oil, food or food additive of the present invention can be provided as an edible oil, food or food additive with a mark indicating that it is a substance for improving and / or preventing a disease that can be improved by HYA, such as obesity, diabetes, lipid metabolism disorders, hyperlipidemia, fatty liver, inflammatory bowel disease (ulcerative colitis, Crohn's disease, pseudomembranous colitis, etc.), ulcer, irritable bowel syndrome, and other various inflammatory diseases (for example: gout, arthritis, polyneuritis, polyradiculitis, hepatitis, bronchitis, pneumonia, nephritis, cystitis, periodontitis, dermatitis, atopic dermatitis, etc.).
[0123] (Pharmaceutical composition of the present invention)
[0124] The present invention provides a pharmaceutical composition containing the compound of the present invention (hereinafter also referred to as "the pharmaceutical composition of the present invention" in this specification).
[0125] The pharmaceutical composition of the present invention can be used in animals as a preventive agent for preventing the following diseases, or as a therapeutic agent for treating, improving, or inhibiting the following diseases, wherein the diseases are diseases that can be improved by using HYA, such as obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, inflammatory bowel disease (ulcerative colitis, Crohn's disease, pseudomembranous colitis, etc.), ulcer, irritable bowel syndrome, and other various inflammatory diseases (such as gout, arthritis, polyneuritis, polyradiculitis, hepatitis, bronchitis, pneumonia, nephritis, cystitis, periodontitis, dermatitis, atopic dermatitis, etc.).
[0126] Here, “animals” include humans, and mammals such as dogs, cats, rabbits, hamsters, rats, mice, cows, pigs, sheep, horses, donkeys, and camels.
[0127] The pharmaceutical composition of the present invention is not particularly limited, and can be provided in the following forms, for example: oral preparations in various dosage forms such as powders, granules, pills, soft capsules, hard capsules, tablets, chewable tablets, rapidly disintegrating tablets, syrups, liquids, suspensions, and emulsions; and non-oral preparations such as suppositories, ointments, creams, gels, patches, inhalants, and injections.
[0128] The pharmaceutical composition of the present invention can be prepared by adding various additives to the compound of the present invention as needed and following conventional pharmaceutical preparation methods, such as the methods described in the sixteenth revised edition of the Japanese Pharmacopoeia General Rules [2], the seventeenth revised edition of the Japanese Pharmacopoeia General Rules [3], etc.
[0129] In the present invention, there are no particular restrictions on additives that can be used for formulation purposes, and examples thereof include: animal and plant oils such as soybean oil, safflower oil, olive oil, germ oil, sunflower oil, butter, and sardine oil; polyols such as polyethylene glycol, propylene glycol, glycerol, and sorbitol; surfactants such as sorbitan fatty acid esters, sucrose fatty acid esters, fatty acid glycerides, and polyglycerol fatty acid esters; solvents such as purified water, sterile purified water, water for injection, physiological saline, ethanol, and isopropanol; lactose, starch, crystalline cellulose, D-mannose, and the like. Excipients such as alcohol, soy lecithin, gum arabic, sorbitol liquid, maltose; binders such as pretreated starch, carboxymethyl cellulose, hydroxypropyl cellulose, shellac; disintegrants such as cross-linked polyvinylpyrrolidone, povidone, dextrin; lubricants such as magnesium silicate, aluminum stearate, talc; sweeteners such as aspartame, licorice extract, saccharin sodium; colorants such as yellow iron oxide, brown iron oxide, black iron oxide, food blue No. 1, food red No. 2; pH adjusters such as hydrochloric acid, citric acid, sodium citrate, potassium hydroxide, sodium hydroxide; flavors such as bitter essence, etc.
[0130] It should be noted that, when a liquid preparation is prepared, a solid preparation which is dissolved or suspended in water or other appropriate solvents and used at the time of use can also be prepared. In addition, tablets and granules can also be coated using a well-known method.
[0131] The pharmaceutical composition of the present invention may be used in combination with the compound of the present invention, within the range not impairing the effects of the present invention, with a therapeutic drug for the above-mentioned diseases that can be improved or prevented by the pharmaceutical composition of the present invention.
[0132] Examples of drugs that can be used in combination with the pharmaceutical composition of the present invention (hereinafter referred to as "combination drugs") include sulfonylurea drugs (tolbutamide, glyburide, glipidazole, glimepiride, etc.), biguanide drugs (metformin hydrochloride, etc.), α-glucosidase inhibitors (voglibose, acarbose, etc.), thiazolidine derivatives (pioglitazone hydrochloride, etc.) and other diabetes therapeutic drugs; statins (pravastatin sodium, simvastatin, pitavastatin calcium, etc.), anion exchange resins (cholestyramine, colestilan, etc.), fibrates (clofibrate, clinofibrate, etc.), nicotinic acid drugs (vitamin E nicotinate, nicotinamide, etc.); salicylic acid preparations (mesalazine, etc.), continuous Sulfonamides (sulfasalazine, etc.), adrenocortical steroids (betamethasone, prednisolone, etc.), molecular targeted therapy drugs (infliximab, adalimumab, etc.), immunosuppressants (azathioprine, etc.), etc., for the treatment of inflammatory bowel diseases (Crohn's disease, ulcerative colitis, pseudomembranous colitis, etc.); anticholinergic drugs (pentasyl hydrochloride, benzylmethoxazole, etc.), gastrointestinal motility regulators (trimebutine, etc.), synthetic polymer compounds (calcium polycarbophil, etc.), lactic acid bacteria preparations, etc., for the treatment of irritable bowel syndrome; gout attack preventive drugs (colchicine, etc.), uric acid excretion promoters (probenecid, bucolome, benzbromarone, etc.), uric acid production inhibitors (allopurinol, etc.), etc.; non-steroidal anti-inflammatory drugs (non-steroidal anti-inflammatory drugs, non ... Arthritis and neuritis treatment drugs such as anti-inflammatory drugs (mefenamic acid, ketoprofen, diclofenac sodium, etc.), bioactive drugs (cyclosporine, etc.); hepatitis treatment drugs such as interferon preparations (interferon β, interferon α-2a, etc.), anti-hepatitis virus drugs (ribavirin, lamivudine, etc.), liver function improvement drugs (glycyrrhizin preparations, glucuronic acid, tiopronin, etc.); bronchitis treatment drugs such as β-stimulants (ephedrine hydrochloride, dl-methylephedrine hydrochloride, trotoquinol hydrochloride, etc.), theophylline drugs (dihydroxypropylphylline, aminophylline, etc.), anticholinergic drugs (tiotropium bromide hydrate, etc.); pneumonia treatment drugs such as macrolide antibiotics (clarithromycin, azithromycin, etc.), new quinolone antibiotics (levofloxacin, garenoxacin, etc.); blood Nephritis treatment drugs such as angiotensin converting enzyme inhibitors (enalapril maleate, delapril hydrochloride, etc.), angiotensin II receptor antagonists (losartan potassium, candesartan cilexetil, etc.); cystitis treatment drugs such as new quinolone antibiotics (ofloxacin, levofloxacin, norfloxacin, etc.), penicillin antibiotics (amoxicillin, ampicillin, cloxacillin, etc.), cephalosporin antibiotics (cephalexin hydrochloride, ceftriaxone hydrochloride, etc.), traditional Chinese medicine (Bawei Dihuang Pills, Zhuling Decoction, etc.); periodontal disease treatment drugs such as cephalosporin antibiotics (cephalexin, etc.), bactericides (benzethonium chloride, chlorhexidine hydrochloride, etc.); dermatitis and atopic dermatitis treatment drugs such as non-steroidal anti-inflammatory drugs (bufenamic acid, flufenamic acid butyl, etc.), antipruritic drugs (crotamiton, etc.);Immunomodulators (tacrolimus hydrate, etc.) and other atopic dermatitis treatment drugs;
[0133] When the pharmaceutical composition of the present invention is made into a non-oral preparation such as an injection, the composition is not particularly limited, and is preferably administered intravenously, intraperitoneally, intramuscularly, subcutaneously, percutaneously, intraarticularly, intrasynovially, intraperiosteally, sublingually, orally, and is particularly preferably administered intravenously or intraperitoneally. Intravenous administration can be any of drip injection and push injection.
[0134] The content of the compound of the present invention in the pharmaceutical composition of the present invention is 5 to 100 wt %, preferably 10 to 90 wt %, and more preferably 20 to 80 wt % relative to the total amount of the pharmaceutical composition of the present invention.
[0135] The dosage of the pharmaceutical composition of the present invention can be appropriately determined according to the type, age and weight of the animal to be administered, the condition and severity, the dosage form of the pharmaceutical composition, the method of administration, the type of combined drug, etc. For example: when the pharmaceutical composition of the present invention is orally administered to humans, it can be administered in the range of 0.02 mg / kg to 100 mg / kg body weight per day for adults, preferably in the range of 0.2 mg / kg to 50 mg / kg body weight, based on the total amount of HYA converted as an active ingredient. In addition, when it is administered to humans non-orally, it can be administered in the range of 0.002 mg / kg to 50 mg / kg body weight, preferably in the range of 0.02 mg / kg to 50 mg / kg body weight. The above amount can be administered once a day or divided into multiple times (2 to 5 times) regardless of oral or non-oral administration.
[0136] The administration period of the pharmaceutical composition of the present invention can be appropriately determined according to the state, condition, severity of the animal to be administered, and is generally 1 to 90 days, preferably 7 to 30 days.
[0137] (Cosmetics or cosmetic additives of the present invention)
[0138] The present invention provides a cosmetic or a cosmetic additive containing the compound of the present invention (hereinafter, in this specification, also referred to as "the cosmetic or cosmetic additive of the present invention").
[0139] The cosmetic of the present invention can be produced by adding various additives to the compound of the present invention as required, based on the above-mentioned method for producing the pharmaceutical composition.
[0140] The cosmetics of the present invention can be made into skin cosmetics such as creams, gels, emulsions, beauty essences, lotions, microemulsion essences, and facial masks; color cosmetics such as foundations, lipsticks, eye shadows, and blushers; cleansing cosmetics such as cleansing oils and cleansing creams; hair cosmetics such as shampoos and conditioners; and various forms of cosmetics such as bath preparations.
[0141] To the cosmetics of the present invention, active ingredients such as anti-wrinkle / anti-aging agents, anti-inflammatory agents, skin roughness preventive agents, cell activation / wound healing agents, whitening agents, oils (animal and plant oils and fats, waxes, esters, higher fatty acids, higher aliphatic alcohols, etc.), surfactants, solvents, thickeners, moisturizers, antioxidants, preservatives, pH adjusters, pigments, fragrances, etc., which are additives commonly used in cosmetics, can be added within the range that does not impair the characteristics of the present invention.
[0142] The cosmetic additive of the present invention can be prepared into an oily, suspension, emulsion, paste, powder, granular or other form by adding the above-mentioned oil, surfactant, solvent, thickener, pigment, etc. to the compound of the present invention as needed, based on the above-mentioned method for producing the pharmaceutical composition.
[0143] The content of the compound of the present invention in the cosmetic or cosmetic additive of the present invention is 5 to 70% by weight, preferably 10 to 60% by weight, and more preferably 20 to 50% by weight, based on the total amount of the cosmetic etc. of the present invention.
[0144] (Feed or feed additive of the present invention)
[0145] The present invention provides a feed or a feed additive containing the compound of the present invention (hereinafter also referred to as "the feed or feed additive of the present invention" in this specification).
[0146] The feed or feed additive of the present invention can be prepared in the form of oil, suspension, emulsion, gel, powder, granule, tablet and the like.
[0147] Examples of the feed or feed additive of the present invention include pet food, livestock or aquaculture feed additives, and the like.
[0148] The feed or feed additive of the present invention can be prepared by mixing the compound of the present invention with feed excipients, diluents, etc. according to a common method.
[0149] As for the excipients and diluents for feed, any excipients and diluents can be used without particular limitation as long as they do not destroy the characteristics of the present invention, and examples thereof include: polysaccharides such as gum arabic, carrageenan, agar, xanthan gum, chitosan, cellulose, and locust bean gum; monosaccharides or disaccharides such as glucose, lactose, maltose, and sucrose; sugar alcohols such as glycerol, sorbitol, and D-mannitol; proteins such as albumin, casein, gluten, and gelatin; grain flours such as soybean meal, flour, soybean meal, and corn meal; yeasts such as brewer's yeast, baker's yeast, and brewer's yeast; fats and oils such as hydrogenated oil, vegetable oils and animal oils; clay minerals such as kaolin, zeolite, talc, vermiculite, and bentonite; silicic acid or salts thereof such as diatomaceous earth, hydrous silicon dioxide, silicic acid, light silicon dioxide, silicon dioxide, calcium silicate, and magnesium silicate; hydrocarbons such as light liquid paraffin and liquid paraffin; waxes such as carnauba wax, and the like.
[0150] In addition, as long as the characteristics of the present invention are not destroyed, amino acids such as glycine, DL-alanine, sodium L-glutamate or their salts; vitamins such as L-ascorbic acid, ergocalciferol, thiamine hydrochloride, cholecalciferol, vitamin A powder, vitamin D powder, riboflavin; minerals such as potassium chloride, ferric citrate, calcium gluconate; additives for supplementing nutrients such as pigments such as astaxanthin and canthaxanthin can be further added to the feed or feed additive of the present invention.
[0151] The content of the compound of the present invention in the feed or feed additive of the present invention is 1 to 70 wt %, preferably 3 to 50 wt %, more preferably 5 to 30 wt % relative to the total amount of the feed of the present invention.
[0152] Example
[0153] The present invention will be described in more detail below with reference to Examples and Experimental Examples, but the present invention is not limited thereto and may be modified without departing from the scope of the present invention.
[0154] In the following examples, proton NMR ( 1 H NMR) spectra were measured using AVANCE III500 manufactured by Bruker Corporation, using deuterated chloroform as the solvent. 1 H NMR data are reported as chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, tt = triplet of triplet, brs = broad singlet, sep = septuple), coupling constant (Hz), integration, and assignment.
[0155] High-resolution mass spectrometry was performed using a high-performance liquid chromatography-mass spectrometer (LCMS) (LCMS-2020) manufactured by Shimadzu Corporation.
[0156] The melting point (mp) was measured using a melting point meter (MP-J3) manufactured by Anatec Yanaco Co., Ltd.
[0157] In the following examples, compounds (1) to (3) of the present invention were prepared according to the above-mentioned Preparation Method 1. Alkanols (ethanol, propanol, and ethylene glycol) used in the preparation of the compounds of the present invention were commercially available products (produced by Wako Pure Chemical Industries, Ltd.), and HYA was prepared and used by the method described in Patent Document 2. Other raw material compounds and reagents may be commercially available products as they are, or may be prepared according to a method known per se or a method based thereon.
[0158] [Example 1] Compound (1) of the present invention: 10-hydroxy-cis-12-octadecenoic acid ethyl ester
[0159] HYA (5 g), ester exchange enzyme (lipase) (Novozymes, Lipozyme RMIM, 1 g), and ethanol (5 g) were added to a 100 mL reaction container (medium bottle), and the gas phase of the reaction system was replaced with nitrogen, followed by stirring at 40° C. for 28 hours. After filtering with filter paper to remove the ester exchange enzyme, the mixture was concentrated to obtain 10-hydroxy-cis-12-octadecenoic acid ethyl ester (5.5 g; yield 100%).
[0160] Melting point: below -20℃;
[0161] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 3H, J=6.9Hz), 1.30 (m, 19H), 1.46 (m, 2H), 1.61 (tt, 2H, J=7.3, 7.3Hz), 2.05 (dt, 2H, J=7.0, 7.3Hz), 2.21 (dd, 2H , J=6.8, 6.8Hz), 2.28 (t, 2H, J=7.6Hz), 3.61 (tt, 1H, J=5.9, 6.0Hz), 4.12 (q , 2H, J=7.2Hz), 5.40 (dt, 1H, J=7.5, 11.0Hz), 5.57 (dt, 1H, J=7.4, 10.9Hz);
[0162] MS(ESI):M + 326.
[0163] [Example 2] Compound (1) of the present invention: 10-hydroxy-cis-12-octadecenoic acid propyl ester
[0164] HYA (0.5 g), ester exchange enzyme (lipase) (Novozymes, Lipozyme RMIM, 0.1 g), and propanol (0.5 g) were added to a 100 mL reaction vessel (culture bottle), and the gas phase of the reaction system was replaced with nitrogen, and then stirred at 40° C. for 14.5 hours. After filtering with filter paper to remove the ester exchange enzyme, the mixture was concentrated to obtain 10-hydroxy-cis-12-octadecenoic acid propyl ester (0.5 g; yield 88%).
[0165] Melting point: below -20℃;
[0166] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 3H, J=6.9Hz), 0.95 (t, 3H, J=7.4Hz), 1 .30 (m, 16H), 1.47 (m, 2H), 1.64 (m, 4H), 2.05 (dt, 2H, J=5.7, 7.6Hz), 2.21 (dd , 2H, J=6.6, 6.6Hz), 2.30 (t, 2H, J=7.6Hz), 3.61 (tt, 1H, J=5.9, 6.0Hz), 4.02 (t, 2H, J=6.7Hz), 5.40 (dt, 1H, J=6.8, 10.9Hz), 5.57 (dt, 1H, J=7.3, 10.9Hz);
[0167] MS(ESI):M + 340.
[0168] [Example 3] Compound (2) of the present invention: ethylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester and compound (3) of the present invention: ethylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester
[0169] HYA (0.5 g), transesterification enzyme (lipase) (Novozymes, Lipozyme RMIM, 0.1 g), and ethylene glycol (260.7 mg) were added to a 100 mL reaction container (culture bottle), and the gas phase of the reaction system was replaced with nitrogen, followed by stirring at 40° C. for 72 hours. After removing the transesterification enzyme by filtration with filter paper, the mixture was separated and purified by medium-pressure silica gel column chromatography ("Rapid Automatic Purification Device Isolera One", manufactured by Biotage, column: "SNAP Ultra", manufactured by Biotage, eluted with hexane:ethyl acetate = 90:10 to 50:50), to obtain ethylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester (315.6 mg) and ethylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester (152.7 mg).
[0170] Ethylene glycol mono(10-hydroxy-cis-12-octadecenoic acid) ester
[0171] Melting point: below 8-9°C;
[0172] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 3H, J = 7.0Hz), 1.30 (m, 16H), 1.46 (m, 2H), 1. 63 (tt, 2H, J = 7.3, 7.3Hz), 1.84 (brs, 1H), 2.05 (dt, 2H, J = 5.2, 6.5Hz), 2.21 (dd, 2H , J=6.5, 6.5Hz), 2.35 (t, 2H, J=7.5Hz), 3.48 (brs, 1H), 3.61 (tt, 1H, J=5.8, 6.2Hz) , 4.21 (t, 2H, J = 1.7Hz), 5.40 (dt, 1H, J = 7.5, 11.0Hz), 5.57 (dt, 1H, J = 7.4, 10.9Hz);
[0173] MS(ESI):M + 342.
[0174] Ethylene glycol di(10-hydroxy-cis-12-octadecenoic acid) ester
[0175] Melting point: 22°C;
[0176] 1 H NMR (CDCl3, 500MHz): (δ)ppm: 0.89 (t, 6H, J=7.0Hz), 1.30 (m, 32H), 1.46 (m, 4H), 1.62 (tt, 4H, J=7.1, 9.1Hz), 2.05 (dt, 4H, J=6.1, 7.4Hz), 2.21 (dd, 4H , J=6.7, 6.7Hz), 2.32 (m, 4H), 3.48 (brs, 2H), 3.61 (tt, 2H, J=5.8, 6.3Hz), 4.27 (brs, 4H), 5.40 (dt, 2H, J=7.5, 11.0Hz), 5.57 (dt, 2H, J=7.3, 11.0Hz);
[0177] MS(ESI):M + 623.
[0178] [Comparative Example] 10-Hydroxy-cis-12-octadecenoic acid (HYA)
[0179] As a comparative example, HYA produced by the method described in Patent Document 2 was used.
[0180] [Experimental Example 1]
[0181] Whether the compounds of Examples 1 and 2 and HYA of Comparative Example were liquid or solid at room temperature (15° C. to 25° C.) was confirmed by visual observation.
[0182] As a result, the compounds of Examples 1 and 2 were liquid at room temperature, and HYA of Comparative Example was solid at room temperature.
[0183] Therefore, it was found that the compound of the present invention, which is obtained by converting 10-hydroxy-cis-12-octadecenoic acid (HYA) into an ethyl ester or a propyl ester, exists in a liquid state at room temperature.
[0184] [Experimental Example 2]
[0185] The taste of the compound of Example 1 and HYA of Comparative Example was subjected to sensory evaluation (hereinafter referred to as taste test) by 10 panelists. After taking 5 mg of the sample (the sample name was concealed from the panelists during the test), the panelists evaluated the five tastes (delicious, bitter, sour, salty, and sweet), irritation, and oiliness, and further performed a comprehensive evaluation.
[0186] Each evaluation was made into 5 levels as described below, and the average value of the scores of 10 judges was calculated.
[0187] Five tastes (delicious, bitter, sour, salty, sweet): strong (5 points) to weak (1 point)
[0188] Irritation: Weak (5 points) to Strong (1 point)
[0189] Oil smell: weak (5 points) ~ strong (1 point)
[0190] Overall evaluation: delicious (5 points) ~ unpalatable (1 point)
[0191] As shown in Table 1 below, the results showed that the HYA of the comparative example had a strong irritation and a moderate oily taste, whereas the compound of Example 1 of the present invention was evaluated as having a higher delicious taste and sweetness than the comparative example, and the irritation was significantly reduced and the oily taste was slightly reduced. Furthermore, the overall evaluation was also high.
[0192] [Table 1]
[0193]
[0194] The above results show that the compound of the present invention exists in a liquid form at room temperature due to the lowering of the melting point. In addition, it can be confirmed that the compound of Example 1 has no irritation and exhibits a strong taste.
[0195] Industrial Applicability
[0196] It was found that the compound of the present invention is liquid at room temperature, tastes good, and is easy to take in and handle. In addition, after taking in, the compound of the present invention hydrolyzes the ester bond in the body by lipase or the like to release HYA, so it is expected to exert excellent physiological functions (improvement of lipid metabolism abnormalities, improvement of intestinal immunity, inhibition of intestinal inflammation, etc.) in the same manner as taking HYA alone, and therefore, it is extremely industrially applicable in that it can be used as an edible oil and fat that utilizes the above functions, can be used as various foods and food additives, and can be used in various fields such as pharmaceuticals, cosmetics, and feed.
[0197] This application is based on Japanese Patent Application No. 2015-112606 filed in Japan, and all the contents are incorporated herein by reference.
Claims
1. Edible fats and oils, comprising 10-hydroxy-cis-12-octadecenoic acid ethyl ester or an optical isomer thereof.
2. Food or food additive containing 10-hydroxy-cis-12-octadecenoic acid ethyl ester or its optical isomers.
3. A pharmaceutical composition comprising 10-hydroxy-cis-12-octadecenoic acid ethyl ester or an optical isomer thereof.
4. A preventive or therapeutic agent for a disease, comprising 10-hydroxy-cis-12-octadecenoic acid ethyl ester or an optical isomer thereof, wherein the disease is selected from obesity, diabetes, abnormal lipid metabolism, hyperlipidemia, fatty liver, ulcerative colitis, Crohn's disease, ulcer, irritable bowel syndrome, and inflammatory diseases.
5. A cosmetic or a cosmetic additive comprising ethyl 10-hydroxy-cis-12-octadecenoate or an optical isomer thereof.
6. A feed or feed additive comprising 10-hydroxy-cis-12-octadecenoic acid ethyl ester or an optical isomer thereof.
Citation Information
Patent Citations
Lipid-improving agent and composition comprising the lipid-improving agent
JP2006521368A
Method for producing oxo fatty acid and rare fatty acid
WO2013168310A1
Process for preparing sebacic acid
WO2014037328A1
Metabolism-improving agent comprising rare fatty acid
WO2014069227A1
Intestinal tract-protecting agent containing hydroxylated fatty acid
WO2014129384A1
